Cryo-Cell to Spin-off Celle Corp., Its Subsidiary Holding Assets Not Directly Associated with Recurring Revenue from Biopreservation
Celle Corp. holds certain assets of Cryo-Cell not directly associated with its recurring revenue derived from privately banked cord blood specimens.
OLDSMAR, Fla.–Cryo-Cell International, Inc. (NYSE American LLC: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. [Read more…]
Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer
Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery.
San Diego, CA, April 1, 2024 – Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. This product introduces a reliable solution for researchers in stem cell research and biotechnology, focusing on enhancing cell viability. [Read more…]
Endonovo Therapeutics Files Patent Application for Cell Therapy Created Using Cord Blood and Tissue Derived Cells
Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells
LOS ANGELES, CA– Oct 27, 2015 – Endonovo Therapeutics, Inc. (OTCQB: ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it has filed a patent application with the United States Patent and Trademark Office (USPTO) on a perivascular cell mixture created using its proprietary Cytotronics™ Platform that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders. [Read more…]
Fujifilm Investing $200M to Expand CDMO Services and Double Capacity for iPSC-derived Therapeutics
The investment will double FUJIFILM Cellular Dynamics’s manufacturing capacity for iPSC-derived cell therapies for its partners. New headquarters will include iPSC manufacturing for drug discovery, drug efficacy, and pharmacology applications.
FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, CA, will be expanded to support cell therapy CDMO services.
- 1
- 2
- 3
- …
- 96
- Next Page »